Javascript must be enabled to continue!
Integrative Single‐Cell and Spatial Transcriptomics Reveals the Crosstalk of CTHRC1+ CAF and MMP7+ Epithelial Axis as a Potential Therapeutic Target and Predicts Poor Clinical Outcomes in Colorectal Cancer
View through CrossRef
Background
Colorectal cancer (CRC) progression is heavily influenced by the tumor microenvironment (TME), where cancer‐associated fibroblasts (CAFs) are key players. However, the heterogeneity, plasticity, and functional roles of CAFs in CRC remain poorly understood.
Methods
We integrated single‐cell RNA sequencing (scRNA‐seq) data from four public CRC datasets and spatial transcriptomics data. Using computational approaches such as Harmony, Monocle2, and CellChat algorithms, we analyzed cellular landscapes, CAF subtype identification, developmental trajectories, transcription factor networks, and cell–cell communications to reveal CAF heterogeneity and their crosstalk with other cell subtypes in CRC.
Results
We identified eight distinct CAF subtypes with unique gene expression profiles and developmental plasticity. The CTHRC1+ CAF subtype was significantly associated with T cell exclusion and upregulated expression of immune checkpoint genes. We uncovered a specific communication axis between CTHRC1+ CAFs and MMP7+ malignant epithelial (Malig‐Epi) cells mediated by the thrombospondin (THBS)2‐SDC4 ligand–receptor signaling. High infiltration of both cell types synergistically correlates with worse prognosis and unfavorable response to immunotherapy.
Conclusions
Our study delineates CAF heterogeneity in CRC and highlights the CTHRC1+ CAF subtype as a critical organizer of an immunosuppressive niche. The THBS2‐SDC4 signaling pathway between CTHRC1+ CAFs and MMP7+ epithelial cells acts as a potential therapeutic target to disrupt protumorigenic crosstalk and improve clinical outcomes for CRC patients.
Title: Integrative Single‐Cell and Spatial Transcriptomics Reveals the Crosstalk of CTHRC1+ CAF and MMP7+ Epithelial Axis as a Potential Therapeutic Target and Predicts Poor Clinical Outcomes in Colorectal Cancer
Description:
Background
Colorectal cancer (CRC) progression is heavily influenced by the tumor microenvironment (TME), where cancer‐associated fibroblasts (CAFs) are key players.
However, the heterogeneity, plasticity, and functional roles of CAFs in CRC remain poorly understood.
Methods
We integrated single‐cell RNA sequencing (scRNA‐seq) data from four public CRC datasets and spatial transcriptomics data.
Using computational approaches such as Harmony, Monocle2, and CellChat algorithms, we analyzed cellular landscapes, CAF subtype identification, developmental trajectories, transcription factor networks, and cell–cell communications to reveal CAF heterogeneity and their crosstalk with other cell subtypes in CRC.
Results
We identified eight distinct CAF subtypes with unique gene expression profiles and developmental plasticity.
The CTHRC1+ CAF subtype was significantly associated with T cell exclusion and upregulated expression of immune checkpoint genes.
We uncovered a specific communication axis between CTHRC1+ CAFs and MMP7+ malignant epithelial (Malig‐Epi) cells mediated by the thrombospondin (THBS)2‐SDC4 ligand–receptor signaling.
High infiltration of both cell types synergistically correlates with worse prognosis and unfavorable response to immunotherapy.
Conclusions
Our study delineates CAF heterogeneity in CRC and highlights the CTHRC1+ CAF subtype as a critical organizer of an immunosuppressive niche.
The THBS2‐SDC4 signaling pathway between CTHRC1+ CAFs and MMP7+ epithelial cells acts as a potential therapeutic target to disrupt protumorigenic crosstalk and improve clinical outcomes for CRC patients.
Related Results
Abstract LB478: Epigenetic inactivation of CTHRC1 promotes immune suppressive microenvironment and cancer metastatic relapse
Abstract LB478: Epigenetic inactivation of CTHRC1 promotes immune suppressive microenvironment and cancer metastatic relapse
Abstract
Most current cancer therapies are largely developed based on the genetic characterization of primary tumors and show limited efficacy against metastatic ...
CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes
CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes
AbstractAccording to the previous reports, the collagen triple helix repeat containing 1 (CTHRC1) causes tumorigenesis by modulating the tumor microenvironment, however, the eviden...
Abstract A85: Collagen triple helix repeat containing-1 enhances the aggressiveness of pancreatic tumor by increased cancer cell motility and adhesiveness
Abstract A85: Collagen triple helix repeat containing-1 enhances the aggressiveness of pancreatic tumor by increased cancer cell motility and adhesiveness
Abstract
Collagen triple helix repeat containing-1 (CTHRC1) is a secreted protein involved in vascular remodeling, bone formation and developmental morphogenesis. CT...
CTHRC1: An Emerging Hallmark of Pathogenic Fibroblasts in Lung Fibrosis
CTHRC1: An Emerging Hallmark of Pathogenic Fibroblasts in Lung Fibrosis
Pulmonary fibrosis is a chronic, progressive, irreversible lung disease characterized by fibrotic scarring in the lung parenchyma. This condition involves the excessive accumulatio...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Comprehensive analysis reveals a CTHRC1-based fourteen-gene signature for prognosis prediction in colon cancer
Comprehensive analysis reveals a CTHRC1-based fourteen-gene signature for prognosis prediction in colon cancer
Abstract
Background: Colon cancer is a malignant gastrointestinal tumor and is still a worldwide leading cause of cancer-related mortality. Owing to the development of high...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
Human tissues comprise trillions of cells that populate a complex space of molecular phenotypes and functions and that vary in abundance by 4–9 orders of magnitude. Relying solely ...

